Immunitas is an immuno-oncology therapeutics company advancing multiple programs to the clinic. Immunitas’ programs are derived from a cross-functional, highly integrated, single cell genomics platform that enables rapid target identification and validation in parallel with antibody discovery and engineering. IMT-009, a first-in-class T & NK cell modulator targeting CD161, is being developed for the treatment of solid tumors and hematological malignancies. The company was founded with leading scientists from Dana Farber, MGH, the Broad, and MIT. In 2019, Immunitas raised a $39M Series A from a strong syndicate of investors including the Longwood Fund, Hillhouse, NVF, Leaps by Bayer, and M Ventures.
Total Funding: N/A
Funding Stage: N/A
Business Stage: Scaling Up
Market: B2C
Company Size: 26 to 50
Founded: 2019
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Immunitas Therapeutics